Cover Image
QR Code

Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer.

Published in:Oncology Nurse-APN/PA Vol. 15; no. 3; p. 21
Main Author: King, William
Format: brief item pictorial Journal Article
Published: Amplity Health Jun2022
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=157282455&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 157282455
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        19449801
        FU64
      jtl: Oncology Nurse-APN/PA
      issn: 19449801
      maglogo: N
    pubinfo:
      dt: Jun2022
      vid: 15
      iid: 3
      pid: 82137
      pub: Amplity Health
      place: East Windsor, New Jersey
    artinfo:
      ui:
        157282455
        157282455
        157282455
        157282455
      ppf: 21
      ppct: 0
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer.
      aug:
        au: King, William
      sug:
        subj:
          Androgen Antagonists Therapeutic Use
          Docetaxel Therapeutic Use
          Antineoplastic Agents, Combined Therapeutic Use
          Prostatic Neoplasms Prognosis
          Neoplasm Metastasis Prognosis
      pubtype: Periodical
      doctype:
        brief item
        pictorial
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N